Applied DNA Sciences, Inc. and Kudo Biotechnology announced their entry into a joint development agreement (the JDA) to integrate Applied DNA's Linea IVT platform (the Platform) into Kudo Bio's commercial mRNA manufacturing workflows. Under the terms of the JDA, the Companies will seek to optimize mRNA quality, yields, and mitigation of contamination by double-stranded RNA (dsRNA) in an integrated workflow at manufacturing scale and establish a global co-marketing relationship. Upon successful completion of the JDA, the Companies plan to negotiate agreements to enable the commercial launch of the joint workflow in the second half of calendar 2024.

The Linea IVT Platform combines Applied DNA's enzymatically produced Linea? DNA IVT templates and its proprietary Linea? RNA polymerase (RNAP), obtained through the recent acquisition of Spindle Biotech, to provide what Applied DNA believes to be numerous advantages over conventional mRNA manufacturing methods, including the prevention or reduction of dsRNA contamination and reduced mRNA manufacturing turn-around-times.